Time on boards
- Boards served
- 4
- Current seats
- 4
- Board service
- 14 years
- Director since
- 2023
14 years of board service in total across 4 boards, counting each seat separately. Longest: Opus Genetics Inc., 3 years.
Opus Genetics Inc.
Director · Interim CEO and President
Novavax Inc.
Director
Ardelyx Inc.
Director
Sagimet Biosciences Inc.
Director
Chief executive roles
Dates unknown
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
| Date | Company | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Jan 16, 2025 | Ardelyx Inc. | Option exercise | +100,000 | $0.55 | $55,000 |
| Oct 29, 2024 | Novavax Inc. | Option exercise | +3,800 | — | — |
| Jun 14, 2024 | Ardelyx Inc. | Grant or award | +12,204 | — | — |
| Jun 12, 2024 | Novavax Inc. | Option exercise | +6,670 | — | — |
| Jun 11, 2024 | Opus Genetics Inc. | Grant or award | +41,143 | — | — |
| Jan 1, 2024 | Opus Genetics Inc. | Grant or award | +24,762 | — | — |
| Nov 1, 2023 | Opus Genetics Inc. | Grant or award | +35,000 | — | — |
| Oct 29, 2023 | Novavax Inc. | Option exercise | +3,800 | — | — |
| Jun 15, 2023 | Ardelyx Inc. | Grant or award | +18,494 | — | — |
| Apr 19, 2023 | Opus Genetics Inc. | Grant or award | +50,000 | — | — |
| Jan 11, 2023 | Opus Genetics Inc. | Grant or award | +20,822 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.